Quoin Pharmaceuticals Secures Second Rare Pediatric Disease Designation for QRX003
Event summary
- FDA grants Rare Pediatric Disease (RPD) Designation to QRX003 for Peeling Skin Syndrome (PSS), a second RPD designation for the drug after Netherton Syndrome.
- Quoin Pharmaceuticals plans to initiate a Phase 2 study for PSS in the second half of 2026, enrolling up to 12 pediatric and adult patients in the U.S. and Europe.
- No approved treatments currently exist for PSS, a rare autosomal recessive genodermatosis causing severe pain and chronic itching.
- Approval of QRX003 for PSS could qualify Quoin for a freely tradable Priority Review Voucher (PRV).
The big picture
Quoin Pharmaceuticals' second RPD designation underscores its focus on rare pediatric diseases, a niche with high unmet medical needs and potential regulatory incentives. The strategic move aligns with broader industry trends toward specialized orphan drug development, where targeted treatments can command premium pricing and faster approvals. The upcoming Phase 2 study will be critical in validating QRX003's efficacy, potentially positioning Quoin as a key player in the rare dermatology space.
What we're watching
- Regulatory Strategy
- How the second RPD designation will impact Quoin's regulatory pathway and potential PRV acquisition.
- Clinical Execution
- The pace at which Quoin can enroll and complete the Phase 2 study for PSS.
- Market Potential
- Whether QRX003's success in PSS could open doors to other rare skin disorders in Quoin's pipeline.